After a slew of M&A deals throughout the first month of 2018, including Celgene’s buyout of Juno Therapeutics for $9 billion and Sanofi’s spending spree to acquire Bioverativ for $11.6 billion and Ablynx for $4.8 billion, many in the industry are asking who will be the next to make a deal. Whoever decides to splash the cash next, it could be to pick up Nektar Therapeutics, who is reported by Bloomberg to be looking into the sale of its business.